上海医药集团股份有限公司 关于2019年A股股票期权激励计划预留股票期权 第三个行权期自主行权结果公告

Core Viewpoint - Shanghai Pharmaceuticals has announced the results of the third exercise period of its 2019 A-share stock option incentive plan, indicating that no stock options were exercised during this period [2][3][4]. Group 1: Stock Option Incentive Plan - The number of stock options available for exercise in the third period is 680,000, with the exercise period running from February 8, 2025, to February 7, 2026 [2]. - No stock options were exercised by the incentive recipients during the third exercise period [3]. - The unexercised stock options from the third exercise period will be canceled by the company [4]. Group 2: Approval Process for the Incentive Plan - The stock option incentive plan underwent several approval processes, including meetings of the board and supervisory board, and received approval from the Shanghai State-owned Assets Supervision and Administration Commission [5][6][7]. - The first grant of stock options was confirmed on December 19, 2019, with subsequent adjustments made to the list of incentive recipients and the number of options granted [10][11]. Group 3: Impact on Financials - As of the end of the third exercise period, the total share capital of the company is 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status or operating results [18].